DP Medical has secured a deal with Sheffield Teaching Hospitals NHS Foundation Trust (STHFT) to become the first NHS trust in the country to adopt ZedScan as part of its cervical cancer care pathway.
This is a really momentous step for the way patients are managed within the cervical cancer care pathway
The ground-breaking system, which includes its patented Electrical Impedance Spectroscopy technology, offers quicker and more-accurate detection of cervical neoplasia delivering results in real-time, enabling clinicians to improve patient management.
ZedScan enables clinicians to make more-informed decisions at a patient’s first visit, thus benefiting both the patient and hospital.
The system also allows for a more-efficient pathway and reduced morbidity for the patient.
The trust has signed a three-year contract with DP Medical to supply the system, which comprises of a hand-held device, software and disposable sensors. This follows the evaluation of over 400 patients at Sheffield Teaching Hospitals NHS Foundation Trust where the ZedScan system was routinely used within a clinical setting.
ZedScan was developed by Zilico, which includes Sheffield Teaching Hospitals NHS Foundation Trust and the University of Sheffield as partners. Both organisations were pivotal to the product’s development and commercialisation.
Rob Atkinson, UK business development manager and ZedScan product specialist for DP Medical, said: “This is a really momentous step for the way patients are managed within the cervical cancer care pathway and we’re delighted that STHFT is the first trust to have fully adopted ZedScan.
“Ensuring NHS clinicians have access to the best technology to improve diagnosis in this area of healthcare is vital - and ZedScan certainly meets that criteria.
We pride ourselves on being at the forefront of healthcare innovation and this news reinforces our status as pioneers in new medical technology
“We are now looking forward to sharing the results of the case study from STHFT to encourage other trusts around the country to consider adopting ZedScan.”
Sir Andrew Cash, chief executive of Sheffield Teaching Hospitals NHS Foundation Trust, added: “We pride ourselves on being at the forefront of healthcare innovation and this news reinforces our status as pioneers in new medical technology – particularly as this was a system developed together at the University of Sheffield and our trust. The ZedScan system has the potential to improve diagnosis and care for patients within the cervical cancer pathway– and I’m delighted it has been developed and adopted here in Sheffield first.”
